Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 304

1.

ICS-formoterol reliever therapy stepwise treatment algorithm for adult asthma.

Beasley R, Braithwaite I, Semprini A, Kearns C, Weatherall M, Harrison TW, Papi A, Pavord ID.

Eur Respir J. 2020 Jan 9;55(1). pii: 1901407. doi: 10.1183/13993003.01407-2019. Print 2020 Jan. No abstract available.

PMID:
31919194
2.

Anti-IL-4/IL-13 for the treatment of asthma: the story so far.

Moran A, Pavord ID.

Expert Opin Biol Ther. 2020 Jan 9. doi: 10.1080/14712598.2020.1714027. [Epub ahead of print]

PMID:
31914819
3.

Optimal Asthma Control: Time for a New Target.

Beasley R, Braithwaite I, Semprini A, Kearns C, Weatherall M, Pavord ID.

Am J Respir Crit Care Med. 2020 Jan 6. doi: 10.1164/rccm.201910-1934CI. [Epub ahead of print]

PMID:
31905013
4.

Dose-response relationship of ICS/fast-onset LABA as reliever therapy in asthma.

Beasley R, Harper J, Bird G, Dunphy H, Semprini A, Pavord ID, Papi A, Weatherall M.

BMC Pulm Med. 2019 Dec 28;19(1):264. doi: 10.1186/s12890-019-1014-4.

5.

An Expert Consensus Framework for Asthma Remission as a Treatment Goal.

Menzies-Gow A, Bafadhel M, Busse WW, Casale TB, Kocks JWH, Pavord ID, Szefler SJ, Woodruff PG, de Giorgio-Miller A, Trudo F, Fageras M, Ambrose CS.

J Allergy Clin Immunol. 2019 Dec 19. pii: S0091-6749(19)31708-7. doi: 10.1016/j.jaci.2019.12.006. [Epub ahead of print]

6.

Sputum microbiomic clustering in asthma and COPD reveals a Haemophilus-predominant subgroup.

Diver S, Richardson M, Haldar K, Ghebre MA, Ramsheh MY, Bafadhel M, Desai D, Cohen ES, Newbold P, Rapley L, Rugman P, Pavord ID, May RD, Barer M, Brightling CE.

Allergy. 2019 Sep 25. doi: 10.1111/all.14058. [Epub ahead of print]

PMID:
31556120
7.

Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma.

Corren J, Castro M, O'Riordan T, Hanania NA, Pavord ID, Quirce S, Chipps BE, Wenzel SE, Thangavelu K, Rice MS, Harel S, Jagerschmidt A, Khan AH, Kamat S, Maroni J, Rowe P, Lu Y, Amin N, Pirozzi G, Ruddy M, Graham NMH, Teper A.

J Allergy Clin Immunol Pract. 2019 Sep 12. pii: S2213-2198(19)30775-5. doi: 10.1016/j.jaip.2019.08.050. [Epub ahead of print]

8.

Defining severe obstructive lung disease in the biologic era: an endotype-based approach.

Martin RJ, Bel EH, Pavord ID, Price D, Reddel HK.

Eur Respir J. 2019 Nov 21;54(5). pii: 1900108. doi: 10.1183/13993003.00108-2019. Print 2019 Nov. Review.

9.

Point-of-care biomarkers in asthma management: Time to move forward.

Alving K, Diamant Z, Lucas S, Magnussen H, Pavord ID, Piacentini G, Price D, Roche N, Sastre J, Thomas M, Usmani O, Bjermer L; Respiratory Effectiveness Group:; Biomarkers Working Group.

Allergy. 2019 Sep 10. doi: 10.1111/all.14045. [Epub ahead of print] No abstract available.

PMID:
31505025
10.

COPD exacerbation phenotypes: The next frontier.

Moran A, Pavord ID.

Respirology. 2019 Aug 29. doi: 10.1111/resp.13693. [Epub ahead of print] No abstract available.

11.

Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations.

Price DB, Bosnic-Anticevich S, Pavord ID, Roche N, Halpin DMG, Bjermer L, Usmani OS, Brusselle G, Ming SWY, Rastogi S.

Clin Transl Allergy. 2019 Aug 21;9:41. doi: 10.1186/s13601-019-0282-7. eCollection 2019.

12.

Resistance to apoptosis underpins the corticosteroid insensitivity of group 2 innate lymphoid cells.

Luo J, Wu Y, Shrimanker R, Go S, Ye Y, Hardman C, Nahler J, Chen YL, Stöger L, Zeng N, Liu W, Reed L, Tolkovsky AM, Klenerman P, Ogg G, Pavord ID, Xue L.

J Allergy Clin Immunol. 2019 Dec;144(6):1722-1726.e10. doi: 10.1016/j.jaci.2019.08.008. Epub 2019 Aug 22. No abstract available.

PMID:
31445099
13.

Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis.

Maspero JF, Katelaris CH, Busse WW, Castro M, Corren J, Chipps BE, Peters AT, Pavord ID, Ford LB, Sher L, Rabe KF, Rice MS, Rowe P, Lu Y, Harel S, Jagerschmidt A, Khan AH, Kamat S, Pirozzi G, Amin N, Ruddy M, Graham NMH, Mannent LP, Teper A.

J Allergy Clin Immunol Pract. 2019 Jul 24. pii: S2213-2198(19)30633-6. doi: 10.1016/j.jaip.2019.07.016. [Epub ahead of print]

14.

Reply to Boulet and Nair: Inhaled Corticosteroids and Adult Asthma.

Beasley R, Harper J, Bird G, Maijers I, Weatherall M, Pavord ID.

Am J Respir Crit Care Med. 2019 Dec 15;200(12):1557-1558. doi: 10.1164/rccm.201907-1408LE. No abstract available.

15.

Prognostic and Predictive Value of Blood Eosinophil Count, Fractional Exhaled Nitric Oxide, and Their Combination in Severe Asthma: A Post Hoc Analysis.

Shrimanker R, Keene O, Hynes G, Wenzel S, Yancey S, Pavord ID.

Am J Respir Crit Care Med. 2019 Nov 15;200(10):1308-1312. doi: 10.1164/rccm.201903-0599LE. No abstract available.

PMID:
31298922
16.

Usability of mepolizumab single-use prefilled autoinjector for patient self-administration.

Bernstein D, Pavord ID, Chapman KR, Follows R, Bentley JH, Pouliquen I, Bradford E.

J Asthma. 2019 Jun 28:1-12. doi: 10.1080/02770903.2019.1630641. [Epub ahead of print]

PMID:
31251090
17.

Blood eosinophil count and GOLD stage predict response to maintenance azithromycin treatment in COPD patients with frequent exacerbations.

Djamin RS, Bafadhel M, Uzun S, Russell REK, Ermens AAM, Kerstens R, Aerts JGJV, Pavord ID, van der Eerden MM.

Respir Med. 2019 Jul - Aug;154:27-33. doi: 10.1016/j.rmed.2019.06.005. Epub 2019 Jun 8.

PMID:
31203097
18.

The acute wheezy adult with airways disease in the emergency department: a retrospective case-note review of exacerbations of COPD.

Russell R, Beer S, Pavord ID, Pullinger R, Bafadhel M.

Int J Chron Obstruct Pulmon Dis. 2019 May 7;14:971-977. doi: 10.2147/COPD.S190085. eCollection 2019.

19.

Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma.

Beasley R, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, Harrison T, Houghton C, Oldfield K, Papi A, Pavord ID, Williams M, Weatherall M; Novel START Study Team.

N Engl J Med. 2019 May 23;380(21):2020-2030. doi: 10.1056/NEJMoa1901963. Epub 2019 May 19.

PMID:
31112386
20.

Asthma progression and mortality: the role of inhaled corticosteroids.

O'Byrne P, Fabbri LM, Pavord ID, Papi A, Petruzzelli S, Lange P.

Eur Respir J. 2019 Jul 18;54(1). pii: 1900491. doi: 10.1183/13993003.00491-2019. Print 2019 Jul. Review.

21.

Controversies in Allergy: Should Severe Asthma with Eosinophilic Phenotype Always Be Treated with Anti-IL-5 Therapies.

Pavord ID, Hanania NA.

J Allergy Clin Immunol Pract. 2019 May - Jun;7(5):1430-1436. doi: 10.1016/j.jaip.2019.03.010. Epub 2019 Apr 5. Review. No abstract available.

PMID:
30962155
22.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019.

Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Criner GJ, Frith P, Halpin DMG, Han M, López Varela MV, Martinez F, Montes de Oca M, Papi A, Pavord ID, Roche N, Sin DD, Stockley R, Vestbo J, Wedzicha JA, Vogelmeier C.

Eur Respir J. 2019 May 18;53(5). pii: 1900164. doi: 10.1183/13993003.00164-2019. Print 2019 May. Review.

PMID:
30846476
23.

Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report.

McDonald VM, Fingleton J, Agusti A, Hiles SA, Clark VL, Holland AE, Marks GB, Bardin PP, Beasley R, Pavord ID, Wark PAB, Gibson PG; participants of the Treatable Traits Down Under International Workshop; Treatable Traits Down Under International Workshop participants:.

Eur Respir J. 2019 May 9;53(5). pii: 1802058. doi: 10.1183/13993003.02058-2018. Print 2019 May. Review.

PMID:
30846468
24.

Fevipiprant, a selective prostaglandin D2 receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function.

Hardman C, Chen W, Luo J, Batty P, Chen YL, Nahler J, Wu Y, Pavord ID, Erpenbeck VJ, Sandham DA, Xue L, Ogg G.

J Allergy Clin Immunol. 2019 Jun;143(6):2329-2333. doi: 10.1016/j.jaci.2019.02.015. Epub 2019 Feb 28. No abstract available.

PMID:
30825466
25.

DP2 antagonism reduces airway smooth muscle mass in asthma by decreasing eosinophilia and myofibroblast recruitment.

Saunders R, Kaul H, Berair R, Gonem S, Singapuri A, Sutcliffe AJ, Chachi L, Biddle MS, Kaur D, Bourne M, Pavord ID, Wardlaw AJ, Siddiqui SH, Kay RA, Brook BS, Smallwood RH, Brightling CE.

Sci Transl Med. 2019 Feb 13;11(479). pii: eaao6451. doi: 10.1126/scitranslmed.aao6451.

26.

Unmet Needs in Severe Asthma Subtyping and Precision Medicine Trials. Bridging Clinical and Patient Perspectives.

Siddiqui S, Denlinger LC, Fowler SJ, Akuthota P, Shaw DE, Heaney LG, Brown L, Castro M, Winders TA, Kraft M, Wagers S, Peters MC, Pavord ID, Walker S, Jarjour NN.

Am J Respir Crit Care Med. 2019 Apr 1;199(7):823-829. doi: 10.1164/rccm.201809-1817PP. No abstract available.

PMID:
30726120
27.

Inhaled Corticosteroid Therapy in Adult Asthma. Time for a New Therapeutic Dose Terminology.

Beasley R, Harper J, Bird G, Maijers I, Weatherall M, Pavord ID.

Am J Respir Crit Care Med. 2019 Jun 15;199(12):1471-1477. doi: 10.1164/rccm.201810-1868CI.

PMID:
30645143
28.

Correction: Synergistic activation of pro-inflammatory type-2 CD8 + T lymphocytes by lipid mediators in severe eosinophilic asthma.

Hilvering B, Hinks TSC, Stöger L, Marchi E, Salimi M, Shrimanker R, Liu W, Chen W, Luo J, Go S, Powell T, Cane J, Thulborn S, Kurioka A, Leng T, Matthews J, Connolly C, Borg C, Bafadhel M, Willberg CB, Ramasamy A, Djukanović R, Ogg G, Pavord ID, Klenerman P, Xue L.

Mucosal Immunol. 2019 Mar;12(2):581. doi: 10.1038/s41385-018-0121-5.

PMID:
30518781
29.

Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids.

Siddiqui SH, Pavord ID, Barnes NC, Guasconi A, Lettis S, Pascoe S, Petruzzelli S.

Int J Chron Obstruct Pulmon Dis. 2018 Nov 6;13:3669-3676. doi: 10.2147/COPD.S179425. eCollection 2018.

30.

Exacerbations of severe asthma in patients treated with mepolizumab.

Shrimanker R, Pavord ID, Yancey S, Heaney LG, Green RH, Bradding P, Hargadon B, Brightling CE, Wardlaw AJ, Haldar P.

Eur Respir J. 2018 Dec 13;52(6). pii: 1801127. doi: 10.1183/13993003.01127-2018. Print 2018 Dec. No abstract available.

PMID:
30464012
31.

Oral corticosteroid-dependent asthma: current knowledge and future needs.

Pavord ID.

Curr Opin Pulm Med. 2019 Jan;25(1):51-58. doi: 10.1097/MCP.0000000000000541.

PMID:
30461530
32.

Do we really need a new classification of airway diseases?

Agusti A, Pavord ID.

Lancet Respir Med. 2018 Dec;6(12):891-893. doi: 10.1016/S2213-2600(18)30386-2. Epub 2018 Nov 9. No abstract available.

PMID:
30420248
33.

Remotely Monitored Therapy and Nitric Oxide Suppression Identifies Nonadherence in Severe Asthma.

Heaney LG, Busby J, Bradding P, Chaudhuri R, Mansur AH, Niven R, Pavord ID, Lindsay JT, Costello RW; Medical Research Council UK Refractory Asthma Stratification Programme (RASP-UK).

Am J Respir Crit Care Med. 2019 Feb 15;199(4):454-464. doi: 10.1164/rccm.201806-1182OC.

PMID:
30339770
34.

Association between blood eosinophil count and risk of readmission for patients with asthma: Historical cohort study.

Kerkhof M, Tran TN, van den Berge M, Brusselle GG, Gopalan G, Jones RCM, Kocks JWH, Menzies-Gow A, Nuevo J, Pavord ID, Rastogi S, Price DB.

PLoS One. 2018 Jul 25;13(7):e0201143. doi: 10.1371/journal.pone.0201143. eCollection 2018.

35.

GLUCOLD, eosinophils and chronic obstructive pulmonary disease.

Pavord ID.

Respirology. 2018 Nov;23(11):966-967. doi: 10.1111/resp.13361. Epub 2018 Jun 26. No abstract available.

36.

Will precision medicine become an effective tool for airway disease?

Shrimanker R, Pavord ID.

Per Med. 2018 Jul 1;15(4):243-245. doi: 10.2217/pme-2018-0027. Epub 2018 Jun 21. No abstract available.

PMID:
29927347
37.

Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis.

Psallidas I, Kanellakis NI, Gerry S, Thézénas ML, Charles PD, Samsonova A, Schiller HB, Fischer R, Asciak R, Hallifax RJ, Mercer R, Dobson M, Dong T, Pavord ID, Collins GS, Kessler BM, Pass HI, Maskell N, Stathopoulos GT, Rahman NM.

Lancet Oncol. 2018 Jul;19(7):930-939. doi: 10.1016/S1470-2045(18)30294-8. Epub 2018 Jun 13.

PMID:
29908990
38.

Synergistic activation of pro-inflammatory type-2 CD8+ T lymphocytes by lipid mediators in severe eosinophilic asthma.

Hilvering B, Hinks TSC, Stöger L, Marchi E, Salimi M, Shrimanker R, Liu W, Chen W, Luo J, Go S, Powell T, Cane J, Thulborn S, Kurioka A, Leng T, Matthews J, Connolly C, Borg C, Bafadhel M, Willberg CB, Ramasamy A, Djukanović R, Ogg G, Pavord ID, Klenerman P, Xue L.

Mucosal Immunol. 2018 Sep;11(5):1408-1419. doi: 10.1038/s41385-018-0049-9. Epub 2018 Jun 15. Erratum in: Mucosal Immunol. 2018 Dec 5;:.

39.

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.

Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A.

N Engl J Med. 2018 Jun 28;378(26):2486-2496. doi: 10.1056/NEJMoa1804092. Epub 2018 May 21.

40.

Biologics and chronic obstructive pulmonary disease.

Pavord ID.

J Allergy Clin Immunol. 2018 Jun;141(6):1983-1991. doi: 10.1016/j.jaci.2018.04.020. Epub 2018 May 4. Review.

PMID:
29729941
41.

Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma.

Busse WW, Maspero JF, Rabe KF, Papi A, Wenzel SE, Ford LB, Pavord ID, Zhang B, Staudinger H, Pirozzi G, Amin N, Akinlade B, Eckert L, Chao J, Graham NMH, Teper A.

Adv Ther. 2018 May;35(5):737-748. doi: 10.1007/s12325-018-0702-4. Epub 2018 May 3.

42.

Blood eosinophil levels as a biomarker in COPD.

Brusselle G, Pavord ID, Landis S, Pascoe S, Lettis S, Morjaria N, Barnes N, Hilton E.

Respir Med. 2018 May;138:21-31. doi: 10.1016/j.rmed.2018.03.016. Epub 2018 Mar 15. Review.

PMID:
29724389
43.

Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles.

Ghebre MA, Pang PH, Diver S, Desai D, Bafadhel M, Haldar K, Kebadze T, Cohen S, Newbold P, Rapley L, Woods J, Rugman P, Pavord ID, Johnston SL, Barer M, May RD, Brightling CE.

J Allergy Clin Immunol. 2018 Jun;141(6):2027-2036.e12. doi: 10.1016/j.jaci.2018.04.013. Epub 2018 Apr 28.

44.

Associations between blood eosinophils and decline in lung function among adults with and without asthma.

Hancox RJ, Pavord ID, Sears MR.

Eur Respir J. 2018 Apr 19;51(4). pii: 1702536. doi: 10.1183/13993003.02536-2017. Print 2018 Apr.

45.

Mepolizumab for Eosinophilic COPD.

Sciurba FC, Bradford ES, Pavord ID.

N Engl J Med. 2018 Feb 15;378(7):681-683. doi: 10.1056/NEJMc1715454. No abstract available.

PMID:
29443666
46.

COUNTERPOINT: Should an Attempt Be Made to Withdraw Inhaled Corticosteroids in All Patients With Stable GOLD 3 (30% ≤ FEV1 < 50% Predicted) COPD? No.

Pavord ID.

Chest. 2018 Apr;153(4):782-784. doi: 10.1016/j.chest.2018.01.030. Epub 2018 Feb 2. No abstract available.

PMID:
29410364
47.

Rebuttal From Dr Pavord.

Pavord ID.

Chest. 2018 Apr;153(4):786-787. doi: 10.1016/j.chest.2018.01.026. Epub 2018 Feb 2. No abstract available.

PMID:
29410251
48.

'We can't diagnose asthma until <insert arbitrary age>'.

Bush A, Pavord ID.

Arch Dis Child. 2018 Aug;103(8):729-731. doi: 10.1136/archdischild-2017-314180. Epub 2018 Jan 5. No abstract available.

49.

A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial.

Hanratty CE, Matthews JG, Arron JR, Choy DF, Pavord ID, Bradding P, Brightling CE, Chaudhuri R, Cowan DC, Djukanovic R, Gallagher N, Fowler SJ, Hardman TC, Harrison T, Holweg CT, Howarth PH, Lordan J, Mansur AH, Menzies-Gow A, Mosesova S, Niven RM, Robinson DS, Shaw DE, Walker S, Woodcock A, Heaney LG; RASP-UK (Refractory Asthma Stratification Programme) Consortium.

Trials. 2018 Jan 4;19(1):5. doi: 10.1186/s13063-017-2384-7.

50.

Evaluation of Potential Continuation Rules for Mepolizumab Treatment of Severe Eosinophilic Asthma.

Gunsoy NB, Cockle SM, Yancey SW, Keene ON, Bradford ES, Albers FC, Pavord ID.

J Allergy Clin Immunol Pract. 2018 May - Jun;6(3):874-882.e4. doi: 10.1016/j.jaip.2017.11.026. Epub 2017 Dec 16.

Supplemental Content

Loading ...
Support Center